PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Ì	e ledimen in les branches and in second	Complete If Known			
	Application Number	10/759,746			
	Filing Date	January 16, 2004			
First Named Inventor Art Unit		E. Femandez-Salas			
		Not Yet Assigned			
	Examiner Name	Not Yet Assigned			
1	Attorney Docket Number	ALLE0014-104 (17335CIP4(BOT))			

		·	U.S. PATENT		
	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Examiner Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
CYW	AA	US-6,458,365	10/01/2002	Aoki, et al	
	AB	US- 5,766,605	06/16/1998	Sanders et al	
	AC	US- 5,714,468	02/03/1998	Dao	<u> </u>
_	AD	US- 6,464,986	10/15/2002	Aoki et al	
	AE	US- 6,113,915	09/05/2000	Aoki et al	
-	AF	US- 6,306,403	10/23/2001	Donovan	
-	AG	US- 6,299,893	10/09/2001	Schwartz et al	
	AH	US- 5,670,484	09/23/1997	Binder	
	Al	US- 6,423,319	07/23/2002	Brooks et al	
+	AJ	US- 6,139,845	10/31/2000	Donovan	<u> </u>
<del></del>	AK	US- 6,143,306	11/07/2000	Donovan	
	AL	US- 5,437,291	08/01/1995	Pasricha et al	
$\dashv$	AM	US- 6,365,164	04/02/2002	Schmidt	
	AN	US- 6,063,768	05/16/2000	First	
$\dashv$	AO	US- 6,395,277	05/28/2002	Graham	
-	AP	US- 6,265,379	07/24/2001	Donovan	
$\dashv$	AQ	US- 6,358,513	03/19/2002	Voet et al	
1,	AR	US- 6,328,977	12/11/2001	Donovan	
₩	AS	US- 6,306,423	10/23/2001	Donovan	
CYW	AT	US- 6,312,708	11/06/2001	Donovan	

FOREIGN PATENT DOCUMENTS						
	0.7-	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner . Initials*		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)		Applicant of Cited Document	Passages or Relevant Figures Appear	T⁰
CYW	BD	WO94/15629	07/21/94	AS Synapse Biol.	·	
						-
	·			<u> </u>	<del>                                     </del>	

		Date	,
Examiner Signature	/Chang-Yu Wang/	Considered	04/24/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.
This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/PTO		Complete If Known	
2300110			Application Number	10/759,746
INFO	RMATION D	ISCLOSURE	Filing Date	January 16, 2004
	STATEMENT BY APPLICANT		First Named Inventor	E. Fernandez-Salas
SIA	I LIVILIA I DI	Al I Eleviti	Art Unit	Not Yet Assigned
	(Use as many sheets	as necessary)	Examiner Name	Not yet Assigned
Sheet		of 7	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))

			U.S. PATENT	OCUMENTS		
Examiner	Cito	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials *	No.	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		Figures Appear	
CYW	AU	US-5,053,005	10/01/1991	. Borodic		
1	AV	US- 5,174,468	02/03/1998	Binder		
	AW	US- 5,721,215	02/24/1998	Aoki et al		
	AX	US- 5,989,545	11/23/1999	Foster et al		
<del></del>	AY	US- 6,113,915	09/05/2000	. Aoki et al		
+-	AZ	US- 5,939,070	08/17/1999	Johnson et al		
7/7	BA	US- 5,768,605	08/16/1998	Sanders et al		
₩	BB	US- 5,437,291	08/11/1995	Pasricha et al		
CYW	BC	US- 4,932,936	06/12/1990	Dykstra et al. `		
CIN	1	.US-				
	<del>                                     </del>	US-				
·····	+-	US-			-	
	1	US-				
	1	US-			,	
		US-		<u> </u>		
	1	US-			ļ	
		US-				
		US-				
	1	US-				
	$\top$	US-				

FOREIGN PATENT DOCUMENTS						
	011-	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)	Date	Applicant of Cited Document	Passages or Relevant Figures Appear	T°
				·		
						<del></del>
				<del></del>	1:	
					<del> </del>	
				<b></b>		
			<del> </del>		<del> </del>	<b>†</b>

Examiner Signature	/Chang-Yu Wang/	Date Considered	04/24/2006	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language the appropriate symbols as indicated.

the appropriate symbols as indicated on the document under WIPO Standard S1. To it possible. Applicant is to place a Gleck mark here it english ranguage Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or ratain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uncluding gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0861-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449B/PTO Application Number .10/759,746 INFORMATION DISCLOSURE January 16, 2004 Filing Date STATEMENT BY APPLICANT E. Fernandez-Salas First Named Inventor Not Yet Assigned Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name ALLE0014-104 (17355CIP4(BOT))

Attorney Docket Number of 7 Sheet NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue T<sup>2</sup> Cite Examiner number(s), publisher, city and/or country where published. No.1 Initials 1 ADENIS, et al., J. Fr. Ophthamol. (1990) 13:259-264. CYW BINZ, et al., J. Biol. Chem. (1990) 265:9153-9158. BF BLITZER, et al., Ann. Otol. Rhinol Laryngol. (1985) 94:591-594. BG BRIN, et al., Advances in Neurology, Vol. 50: Dystonia 2 (1988), pp. 599-608. BH CENCI DI BELLO, et al., Eur. J. Biochem. (1994) 219:161-169. Bi COHN, et al., Neurology (1987) 37 (3 Supp. 1):123-124. вЈ DARSOW, et al., J. Cell Biol. (1998) 142:913-922. вк ELSTON, et al., Br. J. Opthamol. (1985) 69:718-724.

BL

BM

BN

BO

CYW

_				
	Examiner Signature	/Chang-Yu Wang/	Date Considered	04/24/2006

FAUCI, et al., "Harrison's Principles of Internal Medicine, 14th ed., (1998) McGraw-Hill.

ELSTON, et al., Br. J. Opthamol. (1985) 69:891-896.

GALLI, et al., Cell (1998) 9:1437-1448.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449B/PTO 10/759,746 Application Number INFORMATION DISCLOSURE January 16, 2004 Filing Date STATEMENT BY APPLICANT E. Fernandez-Salas First Named Inventor Not Yet Assigned Art Unit Not Yet Assigned Exeminer Name (Use as many sheets as necessary) ALLE0014-104 (17335CIP4(BOT) Attorney Docket Number of 7 Sheet

	-	NON PATENT LITERATURE DOCUMENTS	
xaminer	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		T²
nitials *	100.	JANCOVIC, et al., Neurology (1987) 37:616-623.	
CYW	ВР		
-	BQ	KADKHODAYAN, et al., Protein Express. Purif. (2000) 19:125-130.	ļ
-	BR	KOZAKI, et al., J. Med. Sci. Biol. (1981) 34:61-68.	<u> </u>
_	BS	LACY, et al., Nat. Struct. Biol. (1998) 5:898-802.	
	ВТ	LI, et al., Biochemistry (1994) 33:7014-7020.	
	BU	MAISEY, et al., Eur. J. Biochem. (1988) 177:883-691.	
	BV	MARTINEZ-ARCA, et al., J. Cell Biol. (2000) 149:889-899.	
	BW ·	MILTON, et al., Biochemistry (1992) 31:8799-8809.	-
	вх	MINTON, in Clostridial Neurotoxins: the molecular pathogenesis of tetanus and botulism, Montecucco, ed., Springer Verlag, NY, 1995, pp. 161-194.	
V	ву	PEDEN, et al., J. Biol. Chem. (2001) 276:49183-49187.	ļ.
CYW	BZ	SWAIN, et al., Peptide Res. (1993) 6:147-154.	

Examiner	/Chang-Yu Wang/	Date Considered	04/24/2006
Signature			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

\*This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 37 CFR 1.14. This collection is estimated to take 120 minutes the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief to complete, including gathering, preparing, and submitting the completed application form to the USETO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND. FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons	Complete if Known		
Substitute for form 1449B/PTO	Application Number	10/759,746	
INFORMATION DISCLOSURE	Filing Date	January 16, 2004	
STATEMENT BY APPLICANT	First Named Inventor	E. Fernandez-Salas	
STATEMENT BY ALL ELEVANO	Art Unit	Not Yet Assigned	
A sale an management	Examiner Name	Not Yet Assigned	
(Use as many sheets as necessary)	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))	

		NON PATENT LITERATURE DOCUMENTS	
xaminer	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
IIIIais	<b></b>	ZHOU, et al., Biochemistry (1995) 34:15175-15181.	
CYW	CA ·		
1	СВ	SHIN, et al., J. Biol. Chem. (1991) 266:10658-10665.	
-	cc	RASIBORSKA and CHARLTON, Can. J. Physiol. (1999) 77:679-688.	
	CD	ERDAL, et al., Arch. Pharmacol. (1995) 351:67-78.	
+	CE	RAGONA, et al., The Larangyscope (1999) 109:1344-1346.	
	CF	NAUMANN, et al., Eur. J. Neurol. (1999) 6:S111-S115.	<u> </u>
_	CG	KELLER, et al., FEBS Lett. (1999) 456:137-142.	
	СН	DIETRICH, et al., J. Cell. Biol. (1997) 138:271-281.	
	CI	GEISLER, et al., J. Biol. Chem. (1998) 273:21316-21323.	-
1	C1	TAN, et al., J. Biol. Chem. (1998) 273:17351-17360.	.
CY	CK	LIU, et al., Trends Cell Biol. (1999) 9:356-363.	

1				
	Examiner Signature	/Chang-Yu Wang/	Date Considered	04/24/2006
	1 - 3			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here If English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection is required to confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comment 1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ALADRIDIO.	Complete if Known		
Substitute for form 1449B/PTO	Application Number	10/759,746	
INFORMATION DISCLOSURE	Filing Date	January 16, 2004	
STATEMENT BY APPLICANT	First Named Inventor	E. Fernandez-Salas	
STATEMENT BY ALL LIST	Art Unit	Not Yet Assigned	
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned	
Check 6 of 7	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))	

			NON PATENT LITERATURE DOCUMENTS	
Examir	ner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
CYV	$\neg \uparrow$	CL	CAI and SINGH, Biochemistry (2001) 40:4693.	<u> </u>
Ī	$\neg$	СМ	TIKKANEN, et al., Traffic (2000) 1:631-640.	ļ
$\top$		CN	RAPAPORT, et al., EMBO J. (1998) 17:2148-2155.	-
1		co	MIRANDA, et al., JBC Papers in Press (2001) 1-35.	-
+		СР	COWLES, et al., Ceil (1997) 91:109-118.	<u> </u>
		ca	AOKI, et al., J. Neurol. (2001) 248 (Supp 1):3-10.	-
+		CR	AOKI, Toxicon. (2001) 12:1815-1820.	
		cs	"Protein Turnover and Autograply," American Society for Cell Biology.	
_		СТ	WIEGAND, et al., Nauny Schmiedberg's Arch. Pharmacol. (1976) 292:	-
7	/	cu	HABERMAN, Nauny Schmiedberg's Arch. Pharmacol. (1974) 281:	-
	CYW	CV	THOMPSON, et al., Eur. J. Biochem. (1990) 189:73.	

Examiner Signature	/Chang-Yu Wang/	Date Considered	04/24/2006
Signature			920smonth electrical in conformance

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual to complete, including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions. Alexandria, VA 22313-1450. Do NOT SEND Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. 1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449B/PTO 10/759,746 Application Number INFORMATION DISCLOSURE January 16, 2004 Filing Date STATEMENT BY APPLICANT E. Fernandez-Salas First Named Inventor Not Yet Assigned Art Unit Not Yet Assigned Examiner Name (Use as many sheets as necessary) ALLE0014-104 (17355CIP4(BOT)) Attorney Docket Number of | Sheet

		NON PATENT LITERATURE DOCUMENTS	
xaminer	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Υ 2
nitials *	110.	DI BELLO, et al., Eur. J. Biochem. (1993) 219:161.	
CYW	cw		
<u> </u>	сх	ARNON, et al., "Botulinum toxin as a biological weapon: medical and public health management," JAMA (2001) 285:1059-1070.	
- <del> </del>	CY	ESWARAMOORTHY, et al., "A novel mechanism for Clostridium botulinum neurotoxin inhibition," Biochemistry (2002) 41:9795-9802.	
+	cz	AOKI, et al., "Is the light chain subcellular localization an important factor for Botulinum neurotoxin duration of action?," Naunyn Schmiedebergs Arch. Pharmacol. (2002) 385 (Suppl 2):R10.	
1	DA	FERNANDEZ-SALAS, et al., "Localization of BoNT light chains in neuronal and non-neuronal cell lines, implications for the duration of action of the different serotypes," Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R19.	
CYV	DB	365 (Suppl 2):R19. STEWARD, et al., "BoNT/A light chain and the dileucine motif: potential implications for light chain localization and neurotoxin duration of action," Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R44.	
			_
	-		
<del></del>	-		
			-

Examiner	/Chang-Yu Wang/	Date Considered	04/24/2006
Signature		<u> </u>	to the Marakia conformance

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

<sup>\*</sup>EXAMINER: Initial-lif reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by this collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amou FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPART MENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

	. (	Complete if Known			
	Application Number	10/759,746			
	Filing Date	January 16, 2004			
Ì	First Named Inventor	Lance E. Steward			
	Art Unit	Not Yet Assigned			
	Examiner Name	Not Yet Assigned			
	Attorney Docket Number	ALLE0014-104 (17355 CIP4 BOT)			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
CYW	B1	FERNANDEZ-SALAS, et al., "Plasma Membrane Localization Signals in the Light Chain of Botulinum Neurotoxin," Slide presentation at USAMRDD, January, 2004.	
CYW	B2	FERNANDEZ-SALAS, et al., "Plasma membrane localization signals in the light chain of botulinum neurotoxin," Proc. Natl. Acad. Sci. USA (2004) 101:3208-3213.	
CYW	В3	FERNANDEZ-SALAS, et al., "Is the light chain subcellular localization an important factor in Botulinum toxin duration of action?" Movement Disorders (2004) 19:S23-S34.	
		·	

Examiner Signature	/Chang-Yu Wang/	Date Considered	04/24/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.